Previous 10 | Next 10 |
The USPTO has granted a new patent, No, 10,232,038 to Immutep (NASDAQ: IMMP ), entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response”. More news on: Immutep Limited, Healthcare stocks news, Stocks on the move, Read more ......
SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new...
The following slide deck was published by Immutep Limited in conjunction with this Read more ...
SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that its Chief Medical Off...
Immutep (NASDAQ: IMMP ) is back among after-hours movers, up 11.4% postmarket after reporting positive preclinical data for an antibody developed to treat autoimmune diseases. More news on: Immutep Limited ADR, Healthcare stocks news, Stocks on the move, Read more ...
SYDNEY, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced positive results from its preclinical study of IMP76...
Thinly traded nano cap Immutep Limited ( IMMP -4% ) is down on more than double normal volume, albeit on turnover of only 105K shares, in response to updated Phase 1 results on lead candidate eftilagimod alpha ("efti") (IMP321) in advanced melanoma patients. The data were presented ...
Presented at the World Immunotherapy Congress USA 2019 SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today ...
The First Patient has been dosed at “START Madrid- FJD” in Spain Clinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immute...
Australia's Immutep (NASDAQ: IMMP ) is up 11.4% after hours in U.S. trading after it announced more mature data from an ongoing TACTI-mel Phase I clinical trial. More news on: Immutep Limited ADR, Healthcare stocks news, Stocks on the move, Global news and forex, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
1.55%Change Percent:
Immutep Limited Company Name:
IMMP Stock Symbol:
NASDAQ Market:
Immutep Limited Website:
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA ® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...